Will Immunotherapy Shift the Balance of Treatment for Borderline Resectable Stage III NSCLC Away from Surgery? (BMIC-014)

BeaconMedIC has 73 videos Subscribe Here

Description: Dr. Jack West reviews the implications of the PACIFIC trial that establishes a role for durvalumab immunotherapy in stage III NSCLC, and which will likely lead to some patients shifting away from surgery in favor of chemoradiation followed by durvalumab.
Shared By : BeaconMedIC
Posted on : 11/10/17
Added : 2 years ago
Category : Immunotherapy